Natera, Inc. (NTRA)

業務介紹

納特拉公司(Natera, Inc.)是一家診斷公司,在全球範圍內開發和商業化分子檢測服務。它提供以下產品:

Panorama - 一種無創產前檢測,可通過抽取孕婦的血液篩查胎兒的染色體異常,以及雙胞胎妊娠的單卵雙胞胎狀態。

Vistara - 一種單基因突變篩查檢測,用於識別單基因疾病。

Horizon - 一種攜帶者篩查檢測,用於確定各種遺傳性疾病的攜帶者狀態。

Spectrum - 用於在體外受精週期期間識別染色體異常或遺傳性疾病。

Anora - 一種流產檢測產品,用於分析胎兒染色體以了解流產的原因。

無創親子鑑定 - 通過抽取孕婦和指稱父親的血液,確定親子關係。

Constellation - 一款基於雲端的軟體產品,使實驗室客戶能夠訪問公司的算法和生物信息學,以驗證和推出檢測。

Signatera - 一種循環腫瘤DNA技術,可篩查個人腫瘤的通用突變集。

Prospera - 用於評估器官移植排斥。

納特拉公司通過直銷團隊以及約100個實驗室和分銷合作夥伴網絡提供產品。它與BGI Genomics Co., Ltd.和Foundation Medicine, Inc.有合作協議,共同開發、製造和商業化基於NGS的遺傳檢測和循環腫瘤DNA監測產品。納特拉公司成立於2003年,總部位於德克薩斯州奧斯汀。



Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

公司網址

https://www.natera.com